Raziel Green, 52, an active runner and mother of two, was diagnosed with a rare form of ALS in 2017. Since starting a ...
Zacks Investment Research on MSN5h
IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to SobiIonis Pharmaceuticals IONS signed a license agreement with Sweden-based Sobi. Per the terms, Sobi will acquire exclusive ...
The drug will launch within a week, it said, with no news yet on pricing, although Biogen did tell Reuters it would be in line with other recently launched ALS treatments and out-of-pocket costs ...
Despite past failures, Denali's extensive pipeline and solid financial runway make it a compelling buy at current low stock ...
Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases. Following our analysis of the options activities associated with ...
People diagnosed with amyotrophic lateral sclerosis (ALS), a ... but pharmaceutical company Biogen must still complete additional clinical trials. The drug is not yet covered under public or ...
Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases. In light of the recent options history for Biogen, it's now ...
With its move to MIT’s Volpe Center in Kendall Square, the drugmaker is consolidating its local footprint from three ...
learned about a clinical trial at Mass General for an experimental drug that Biogen in Cambridge, Massachusetts makes. Raziel Green / Fox News “As we look ahead at what’s next for ALS research ...
according to the ALS Association. Soon after her diagnosis, Green learned about a clinical trial at Mass General for an experimental drug — QALSODY® (tofersen), which is made by Biogen in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback